Patent Act (R.S.C., 1985, c. P-4)
Full Document:
- HTMLFull Document: Patent Act (Accessibility Buttons available) |
- XMLFull Document: Patent Act [555 KB] |
- PDFFull Document: Patent Act [1023 KB]
Act current to 2024-10-30 and last amended on 2024-08-19. Previous Versions
SCHEDULE 1(Definition “pharmaceutical product” in section 21.02 and paragraph 21.03(1)(a))
| abacavir (ABC) | tablet, 300 mg (as sulfate); oral solution, 100 mg (as sulfate)/5 mL |
| abacavir + lamivudine + zidovudine | tablet, 300 mg (as sulfate) + 150 mg + 300 mg |
| aciclovir | tablet, 200 mg; powder for injection, 250 mg (as sodium salt) in vial |
| amphotericin B | powder for injection, 50 mg in vial |
| amprenavir | tablet, 150 mg; capsule, 50 mg or 150 mg; oral solution, 15 mg/mL |
| azithromycin | capsule, 250 mg or 500 mg; suspension, 200 mg/5 mL |
| beclometasone | inhalation (aerosol), 50 micrograms per dose (dipropionate) or 250 micrograms (dipropionate) per dose |
| ceftazidime | powder for injection, 250 mg (as pentahydrate) in vial |
| ceftriaxone | injection, 500 mg (as sodium); powder for injection, 250 mg (as sodium salt) in vial |
| ciclosporin | capsule, 25 mg; concentrate for injection, 50 mg/mL in 1-mL ampoule (for organ transplantation) |
| ciprofloxacin | tablet, 250 mg (as hydrochloride) |
| ciprofloxacin | tablet, 250 mg or 500 mg |
| daunorubicin | powder for injection, 50 mg (as hydrochloride) in vial |
| delavirdine | capsule or tablet, 100 mg (as mesylate) |
| didanosine (ddI) | buffered chewable, dispersible tablet, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg; buffered powder for oral solution, 100 mg, 167 mg, 250 mg, packets; unbuffered enteric coated capsule, 125 mg, 200 mg, 250 mg, 400 mg |
| diphtheria antitoxin | injection, 10 000 IU or 20 000 IU in vial |
| diphtheria vaccine | |
| doxorubicin | powder for injection, 10 mg or 50 mg (hydrochloride) in vial |
| efavirenz (EFV or EFZ) | capsule, 50 mg, 100 mg or 200 mg; oral solution, 150 mg/5 mL |
| efavirenz + emtricitabine + tenofovir disoproxil | tablet, 600 mg + 200 mg + 300 mg |
| eflornithine | injection, 200 mg (hydrochloride)/mL in 100-mL bottles |
| emtricitabine + tenofovir disoproxil | tablet, 200 mg + 300 mg |
| enalapril | tablet, 2.5 mg |
| erythromycin | capsule or tablet, 250 mg (as stearate or ethyl succinate); powder for oral suspension, 125 mg (as stearate or ethyl succinate); powder for injection, 500 mg (as lactobionate) in vial |
| etoposide | capsule, 100 mg; injection, 20 mg/mL in 5-mL ampoule |
| factor IX (complex coagulation factors II, VII, IX, X) concentrate | dried |
| hepatitis B vaccine | |
| ibuprofen | tablet, 200 mg or 400 mg |
| indinavir (IDV) | capsule, 200 mg, 333 mg or 400 mg (as sulfate) |
| insulin injection (soluble) | injection, 40 IU/mL in 10-mL vial or 100 IU/mL in 10-mL vial |
| intermediate-acting insulin | injection, 40 IU/mL in 10-mL vial; 100 IU/mL in 10-mL vial (as compound insulin zinc suspension or isophane insulin) |
| isoniazid + pyrazinamide + rifampin | tablet, 50 mg + 300 mg + 120 mg |
| ivermectin | scored tablet, 3 mg or 6 mg |
| lamivudine (3TC) | capsule or tablet, 150 mg; oral solution 50 mg/5 mL |
| lamivudine + nevirapine + zidovudine | tablet, 150 mg + 200 mg + 300 mg |
| lamivudine + zidovudine | tablet, 150 mg + 300 mg |
| levodopa + carbidopa | tablet, 100 mg + 10 mg or 250 mg + 25 mg |
| levofloxacin | tablet, 250 mg or 500 mg |
| lithium carbonate | capsule or tablet, 300 mg |
| lopinavir + ritonavir (LPV/r) | capsule, 133.3 mg + 33.3 mg; oral solution, 400 mg + 100 mg/5 mL |
| metoclopramide | tablet, 10 mg (hydrochloride); injection, 5 mg (hydrochloride)/mL in 2-mL ampoule |
| metronidazole | tablet, 250 mg or 500 mg; injection, 500 mg in 100-mL vial; suppository, 500 mg or 1 g; oral suspension, 200 mg (as benzoate)/5 mL |
| morphine | injection, 10 mg in 1-mL ampoule (sulfate or hydrochloride); oral solution, 10 mg (hydrochloride or sulfate)/5 mL; tablet, 10 mg (sulfate) |
| nelfinavir (NFV) | tablet, 250 mg (as mesilate); oral powder, 50 mg/g |
| nevirapine (NVP) | tablet, 200 mg; oral suspension, 50 mg/5 mL |
| nifedipine | sustained release formulations, tablet, 10 mg |
| nitrofurantoin | tablet, 100 mg |
| ofloxacin | tablet, 200 mg or 400 mg |
| oseltamivir phosphate | capsule, 75 mg; powder for oral suspension, 12 mg/mL |
| potassium chloride | powder for solution |
| ranitidine | tablet, 150 mg (as hydrochloride); oral solution, 75 mg/5 mL; injection, 25 mg/mL in 2-mL ampoule |
| ritonavir | capsule, 100 mg; oral solution, 400 mg/5 mL |
| salbutamol | tablet, 2 mg or 4 mg (as sulfate); inhalation (aerosol), 100 micrograms (as sulfate) per dose; syrup, 2 mg/5 mL; injection, 50 micrograms (as sulfate)/mL in 5-mL ampoule; respirator solution for use in nebulizers, 5 mg (as sulfate)/mL |
| saquinavir (SQV) | capsule, 200 mg |
| stavudine (d4T) | capsule, 15 mg, 20 mg, 30 mg or 40 mg; powder for oral solution, 5 mg/5 mL |
| tenofovir disoproxil | tablet, 300 mg |
| testosterone | injection, 200 mg (enantate) in 1-mL ampoule |
| timolol | solution (eye drops), 0.25% or 0.5% (as maleate) |
| verapamil | tablet, 40 mg or 80 mg (hydrochloride); injection, 2.5 mg (hydrochloride)/mL in 2-mL ampoule |
| zalcitabine | capsule or tablet, 0.375 mg or 0.750 mg |
| zidovudine (ZDV or AZT) | tablet, 300 mg; capsule, 100 mg or 250 mg; oral solution or syrup, 50 mg/5 mL; solution for IV infusion injection, 10 mg/mL in 20-mL vial |
- 2004, c. 23, Sch. 1
- SOR/2005-276
- SOR/2006-204
- SOR/2015-154
- Date modified: